If you have been reading about research chemical and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-01-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Physicochemical behavior influences handling. SR9009 is described as a solid with limited aqueous solubility, so organic solvents such as dimethyl sulfoxide or ethanol are common in research stock solutions. Aqueous dilution can produce precipitates if the organic content is too low. Light, heat, and repeated freeze-thaw cycles may affect stability. Storage recommendations usually specify a desiccated freezer environment protected from light, but exact stability data depend on the formulation and matrix.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also referred to as Stenabolic in non-scientific contexts. |
| Chemical class | Synthetic small molecule | Not a steroid or peptide hormone. |
| Receptor target | REV-ERBα and REV-ERBβ | Nuclear receptor agonist in preclinical studies. |
| Development status | Investigational | No approved human therapeutic indication. |
| Regulatory attention | Prohibited in sport | Listed by anti-doping authorities. |
SR9009 stability depends on temperature, moisture, light, and solvent. Solid material is generally kept cool and dry, while solutions may require protection from repeated warming and cooling. Degradation can appear as color changes, precipitate, or new chromatographic peaks. Researchers should follow supplier instructions and their own stability data. Long-term storage conditions for human use have not been established because the compound lacks approved clinical formulation.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Although samples of ectomycorrhizas are usually taken from the surface horizon due to higher root density, ectomycorrhizas are known to occur in deep tree roots (a depth more than 2 meters), some occurring at least as deep as 4 m. EcM fungal fruiting bodies can be either edible, such as the highly sought-after truffle (Tuber), or deadly, such as death caps and destroying angels (Amanita).
New hostage models were introduced, and the development of the game was further supported with the release of Beta 5.2. With Beta 6.0, new scenarios, such as assassination and escape, were added. While assassination found moderate success, the escape scenario was later removed.
=== Offline combustion and reduction === Conversion to simple molecules (i.e. H2 for hydrogen) is required prior to IRMS for stable isotopes. This is for several reasons with regard to hydrogen: The classical offline preparation for the conversion is combustion over CuO at >800°C in sealed quartz tubes, followed by the isolation of resulting water and the reduction to H2 over hot metal at 400 ~1000°C on a vacuum line. The produced gas is then directly injected into the dual-inlet mass spectrometer for measurement. The metals used for reduction to H2 includes U, Zn, Cr, Mg and Mn, etc. U and Zn had been widely used since the 1950s until Cr was successfully employed in the late 1990s. The offline combustion/reduction has the highest accuracy and precision for HIC measurement without limits for sample types. The analytical uncertainty is typically 1~2‰ in δD. Thus it is still used today when highest levels of precision are required. However, the offline preparation procedure is very time-consuming and complicated. It also requires a large sample (several 100 mg). Thus, online preparation based on combustion/reduction coupled with the subsequent continuous flow-IRMS (CF-IRMS) system has been more often used nowadays. Chromium reduction or high temperature conversion are the dominant online preparation methods for detection of HIC by IRMS.
=== Holland Sweetener Company === A joint venture of DSM and Tosoh, the Holland Sweetener Company manufactured aspartame using the enzymatic process developed by Toyo Soda (Tosoh) and sold as the brand Sanecta. Additionally, they developed a combination aspartame-acesulfame salt under the brand name Twinsweet. They left the sweetener industry in 2006, because "global aspartame markets are facing structural oversupply, which has caused worldwide strong price erosion over the last five years", making the business "persistently unprofitable".
== Production == Hexane is chiefly obtained by refining crude oil. The exact composition of the fraction depends largely on the source of the oil (crude or reformed) and the constraints of the refining. The industrial product (usually around 50% by weight of the straight-chain isomer) is the fraction boiling at 65–70 °C (149–158 °F).
Sources: en.wikipedia.org
=== Biological effects and uses === Studies on mice have helped researchers understand the critical role of ANP in preventing hypertension or high blood pressure. When ANP-deficient mice were studied, they showed signs of hypertension when consuming too much salt. Similarly, when NPR-A, a receptor for ANP, was knocked out in mice, they also displayed hypertension and a reduced response to diuretics. This suggests that ANP is essential in regulating blood pressure and fluid balance. Interestingly, when NPR-A was knocked out specifically in the endothelial cells lining blood vessels, mice showed increased plasma volume, suggesting that ANP may regulate fluid balance by increasing the permeability of blood vessels in these cells. These findings indicate that ANP and its receptor NPR-A are essential in regulating mice's blood pressure and fluid balance. Recent advances in the biology of natriuretic peptides (NPs) have led to the developing of "designer" NPs. These peptides have larger surface areas compared to smaller natural molecules, making them better suited for activating specific receptors with minimal off-target effects. While inhibiting enzymatic degradation of peptides can boost endogenous peptides, it may not be enough to achieve optimal receptor stimulation. Therefore, designer peptides with specific properties could be a new strategy to improve upon existing therapies.
== Awards == Broadbent was elected as a Fellow of the Royal Society Te Apārangi in 2021. The Society said "One of her most notable contributions is the development and testing of healthcare robots, especially for improving outcomes in rest-home and dementia care and chronic illness...this is innovative interdisciplinary work of exceptional quality".
=== Amino acid synthesis === Chloroplasts alone make almost all of a plant cell's amino acids in their stroma except the sulfur-containing ones like cysteine and methionine. Cysteine is made in the chloroplast (the proplastid too) but it is also synthesized in the cytosol and mitochondria, probably because it has trouble crossing membranes to get to where it is needed. The chloroplast is known to make the precursors to methionine but it is unclear whether the organelle carries out the last leg of the pathway or if it happens in the cytosol.
AgNCO + [NH4]Cl → CO(NH2)2 + AgCl This was one of the first artificial syntheses of biological compounds from inorganic starting materials, without the involvement of living organisms. The results of this experiment implicitly discredited vitalism, the theory that the chemicals of living organisms are fundamentally different from those of inanimate matter. This insight was important for the development of organic chemistry. His discovery prompted Wöhler to write triumphantly to Jöns Jakob Berzelius:
=== Physical effects === Common responses include pupil dilation (93%); changes in heart rate (100%), including increases (56%), decreases (13%), and variable responses (31%); changes in blood pressure (84%), including hypotension (34%), hypertension (28%), and general instability (22%); changes in stretch reflex (86%), including increases (80%) and decreases (6%); nausea (44%); tremor (25%); and dysmetria (16%) (inability to properly direct or limit motions). Psilocybin's sympathomimetic or cardiovascular effects, including increased heart rate and blood pressure, are usually mild. On average, peak heart rate is increased by 5 bpm, peak systolic blood pressure by 10 to 15 mm Hg, and peak diastolic blood pressure by 5 to 10 mm Hg. But temporary increases in blood pressure can be a risk factor for users with preexisting hypertension. Psilocybin's somatic effects have been corroborated by several early clinical studies. A 2005 magazine survey of clubgoers in the UK found that over a quarter of those who had used psilocybin mushrooms in the preceding year experienced nausea or vomiting, although this was caused by the mushroom rather than psilocybin itself. In one study, administration of gradually increasing doses of psilocybin daily for 21 days had no measurable effect on electrolyte levels, blood sugar levels, or liver toxicity tests.
Sources: en.wikipedia.org
It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.
No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.
Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.
It is usually detected by LC-MS or HPLC-UV against a reference standard. In biological matrices, metabolite targeting can improve detection. No universal immunoassay is widely available.